ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Open Access
- 1 December 2010
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 18 (6), 548-551
- https://doi.org/10.1016/j.ccr.2010.11.033
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic TumorNew England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Towards patient-based cancer therapeuticsNature Biotechnology, 2010
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorOncogene, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- A small-cell lung cancer genome with complex signatures of tobacco exposureNature, 2009
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007